Combined effects of lutenizing hormone-releasing hormone analogue with antiestrogen on rat mammary tumors

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 145-151

  Matsumoto, Hiroshi ^a   Koibuchi, Yukio ^a   Horiguchi, Jun ^a   Iino, Yuichi ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Breast cancer; DMBA; LH RH analogue; Tamoxifen

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; BUSERELIN; CHOLESTEROL; ESTRADIOL; SOMATOMEDIN C; TAMOXIFEN;

ANIMAL; ARTICLE; BLOOD; EXPERIMENTAL NEOPLASM; FEMALE; IATROGENIC DISEASE; METABOLISM; RAT; RAT STRAIN;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSERELIN; CHOLESTEROL; ESTRADIOL; FEMALE; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 0036133919     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.145     Document Type: Article

References (52)

1. Jordan VC and Koerner S: Tamoxifen (ICI46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205-206, 1975.
2. Jordan VC: Biochemical pharmacology of antiestrogen action. Pharm Rev 36: 245-276, 1984.
3. Coezy E, Borgna JL and Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317-323, 1982. (Pubitemid 12207285)
4. Jordan VC: Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 31: 41-52, 1994.
5. Jiang SY, Parker CJ and Jordan VC: A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 26: 139-148, 1993.
6. Murphy LC: Antiestrogen action and growth factor regulation. Breast Cancer Res Treat 31: 61-71, 1994.
7. Colletti RB, Roberts JD, Devlin JT and Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882-1884, 1989. (Pubitemid 19108421)
8. Lippman ME and Dickson RB: Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 45: 383-440, 1989.
9. Pollak MN: Endocrine effects of IGF-1 on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-217, 1998.
10. Gallo MA and Kaufman D: Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 24 (Suppl 1): S1-71-S1-80, 1997.
11. Li X, Takahashi M, Kushida K and Inoue T: The less potent estrogenic effect of tamoxifen on bone in ovariectomized rats with established osteopenia. Calcif Tissue Int 62: 502-505, 1998. (Pubitemid 28240883)
12. Schwarts LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE and Mittal K: Alterations in steroid hormone receptors in the tamoxifen-treated endothelium. Am J Obstet Gynecol 176: 129-137, 1997. (Pubitemid 127780761)
13. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey FKL, Ma YF, Jee WS and Thompson DD: Comparative effects of droloxifen, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20: 31-39, 1997. (Pubitemid 27046637)
14. MacGregor JI and Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196, 1998.
15. Decensi A, Robertson C, Rotmensz N, Seven G, Maisonneuve P, Sacchini V, Boyle P, Costa A and Veronesi U on behalf of the Italian Chemoprevention Group: Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Br J Cancer 78: 572-578, 1998.
16. Baum M: Tamoxifen, the treatment of choice. Why look for alternatives? Br J Cancer 78 (Suppl 4): 1-4, 1998.
17. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85, 1992.
18. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
19. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group: Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged 50 years or older with breast cancer. J Natl Cancer Inst 88: 1834-1839, 1996.
20. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 (prior annotatin incorrect). J Natl Cancer Inst 86: 527-537, 1994. (Pubitemid 24111008)
21. Fisher B, Dignam J, Bryant J, De Cillis A, Wickerham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J and Lickey HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529-1542, 1996. (Pubitemid 26374506)
22. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549, 1996.
23. Koibuchi Y, Sugamata N, Iino Y, Yokoe T, Andoh T, Maemura M, Takei H, Horiguchi J, Matsumoto H and Morishita Y: The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7,12-dimethylbenz(a) anthracene-induced rat mammary cancer. Int J Mol Med 4: 145-148, 1999.
24. Buzzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, Zilembo N, Di Bartolomeo M, Di Leo A, Arcangeli G, Aitini E, Farina G, Schieppati G, Galluzzo D and Martinetti A: Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Br J Cancer 71: 1111-1114, 1995.
25. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Janicke F, Njordenskold B and Forbes JF: A randomized study to compare the effect of the luteinizing hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and peri-menopausal patients with advanced breast cancer. Eur J Cancer 31: 137-142, 1995.
26. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Jonat W, Kaufmann M, Beex L, Mauriac L, Hoctin-Boes G, Duchateau L and Sylvester R: A new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT). Eur J Cancer 34 (Suppl 5): S90, Abst 405, 1998.
27. Iino Y, Yoshida M, Tago T, Ohwada S, Sugamata N and Horiuchi R: Effects of sequential and combined immunoendocrine therapies using OK-432 (picibanil) and tamoxifen on the growth of 7,12-dimethylbenz(a) anthracene-induced rat mammary carcinoma. Jpn J Clin Oncol 21: 35-38, 1991.
28. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
29. Klijn JGM, Beex LVAM, Mauriac L, Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F and Duchateau L: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92: 903-911, 2000. (Pubitemid 30429190)
30. Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, Matteis A, Zola P, Sismondi P, Francini G, Petrioli R, Sassi M, Pacini P and Galligioni E: Ovarian ablation versus goserelin with or without tamoxifen in pre perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5: 337-342, 1994. (Pubitemid 24142371)
31. Miller WR, Scott WN, Morris R, Fraser HM and Sharpe RM: Growth of human breast cancer cells inhibited by luteinizing hormone-releasing hormone agonist. Nature 313: 231-233, 1985. (Pubitemid 15194060)
32. Blankenstein MA, Henkelman MS and Klijin JGM: Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493-1499, 1985. (Pubitemid 16196242)
33. Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA and Klijn JGM: Combind effects of buserelin, estradiol, and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun 140: 550-556, 1986. (Pubitemid 17190097)
34. Segal T, Kitroser H, Levy J, Schally AV and Sharoni Y: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sei USA 89: 2336-2339, 1992.
35. Plowman PN, Nicholson RI and Walker KJ: Remission of postmenopausal breast cancer during treatment with the luteinizing hormone-releasing hormone agonist ICI 118630. Br J Cancer 54: 903-909, 1986. (Pubitemid 17204440)
36. Schwartz L, Guiochet N and Keiling R: Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. Cancer 62: 2498-2500, 1988. (Pubitemid 19006429)
37. Fekete M, Bajusz S, Groot K, Csernus VJ and Schally AV: Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124: 946-955, 1989. (Pubitemid 19057091)
38. Baumann KH, Kiesel L, Kaufmann M, Bastert G and Runnebaum B: Characterization of binding sites for GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 25: 37-46, 1993. (Pubitemid 23107734)
39. Eidne KA, Flanagan CA, Harris NS and Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425-432, 1987. (Pubitemid 17020904)
40. Segal T, Levy J and Sharoni Y: GnRH analogues stimulate phospholipase C activity in mammary tumor membranes: modulation by GTP. Mol Cell Endocrinol 53: 239-243, 1987. (Pubitemid 17133166)
41. Segal T, Giat J, Levy J and Sharoni Y: Guanine nucleotide modulation of high affinity gonadotropin-releasing hormone receptors in rat mammary tumors. Mol Cell Endocrinol 85: 109-116, 1992.
42. Stoeckemann K and Sandow J: Effects of the luteinizing hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz (a)anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol 119: 457-462, 1993. (Pubitemid 23165051)
43. Crighton IL, Dowsett M, Lal A, Man A and Smith IE: Use of luteinizing hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer. Br J Cancer 60: 644-648, 1989. (Pubitemid 19251468)
44. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP and De Mets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856, 1992.
45. Powles TJ, Hickish T, Kanis JA, Tidy A and Ashley S: Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84, 1996. (Pubitemid 26022463)
46. Furlanetto RW and Di Carlo JN: Somatomedin-C receptors and growth effects in human breast cells maintained in long-term culture. Cancer Res 44: 2122-2128, 1984. (Pubitemid 14145740)
47. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME and Dickson RB: Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46: 4613-4619, 1986. (Pubitemid 16000334)
48. Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
49. Huynh HT, Tetenes E, Wallace L and Pollak M: In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 53: 1727-1730, 1993. (Pubitemid 23127092)
50. Tannenbaum GS, Gurd W, Lapointe M and Pollakk M: Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinol 130: 3395-3401, 1992.
51. Bruning PF, van Doorn J, Bonfrer JMG, van Noord PAH, Korse CM, Linders TC and Hart AA: Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 62: 266-270, 1995.
52. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J and Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentration in human breast cancer. Eur J Cancer 29A: 492-497, 1993. (Pubitemid 23036292)